GRCE — Grace Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
$2.15
+$0.05 (+2.38%)
Grace Therapeutics, Inc. (GRCE) is a biotechnology company listed on NASDAQ. It is led by Prashant Kohli, based in 103 Carnegie Center, Princeton, NJ, United States, 08540, with about 6 employees. Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Net income was -$938.0K. GRCE currently screens at market cap $35.0M.
Use this GRCE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the GRCE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the GRCE SEC filings page. Lician reads the product cache first so this HTML stays unique to Grace Therapeutics, Inc. even when a live quote feed is slow.
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
GRCE Key Statistics
Market Cap
$34.98M
Volume
92,478
Previous Close
$2.18
Day Range
$2.18 – $2.22
EPS
-$0.79
Revenue
$0.00
Net Income
-$9.57M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
6
GRCE Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $100.00M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$9.57M | -$12.85M | -$42.43M | -$9.82M |
| EPS (Diluted) | -$0.79 | -$1.35 | -$5.71 | -$0.27 |
Total Assets
$71.99M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$22.13M
Operating Cash Flow
-$14.90M
Free Cash Flow
$0.00
Grace Therapeutics, Inc. Company Information
- CEO & Director
- Prashant Kohli
- Headquarters
- 103 Carnegie Center, Princeton, NJ, United States, 08540
- Website
- www.gracetx.com
- Phone
- 609-322-1602
- IPO / Founded
- 2024-10-08
- Sector
- Healthcare
- Industry
- Biotechnology